【沃森生物:20价肺炎球菌多糖结合疫苗获临床试验批准】沃森生物公告,公司及子公司共同申请的20价肺炎球菌多糖结合疫苗获得国家药品监督管理局签发的《药物临床试验批准通知书》,通知书编号为2025LP01099。该疫苗是在已上市产品13价肺炎球菌多糖结合疫苗基础上开发的迭代升级产品,新增了8型、10A型、11A型、12F型、15B型、22F型和33F型共计7种血清型,用于预防由本品所含20种肺炎球菌血清型引起的感染性疾病。全球已上市20价肺炎球菌多糖结合疫苗的厂家仅有美国辉瑞公司一家,国内尚未有20价肺炎球菌多糖结合疫苗上市销售。

金融界
18 Apr
沃森生物公告,公司及子公司共同申请的20价肺炎球菌多糖结合疫苗获得国家药品监督管理局签发的《药物临床试验批准通知书》,通知书编号为2025LP01099。该疫苗是在已上市产品13价肺炎球菌多糖结合疫苗基础上开发的迭代升级产品,新增了8型、10A型、11A型、12F型、15B型、22F型和33F型共计7种血清型,用于预防由本品所含20种肺炎球菌血清型引起的感染性疾病。全球已上市20价肺炎球菌多糖结合疫苗的厂家仅有美国辉瑞公司一家,国内尚未有20价肺炎球菌多糖结合疫苗上市销售。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10